Back to Trials
NCT06494033Recruiting

Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients

University of Miami

Start Date

7/3/2024

Completion Date

12/30/2026

Summary

The purpose of this study is to evaluate the clinical outcomes of Cytomegalovirus (CMV) virus in the participants' body. Therefore, the study team will follow the participants' immunological response based on the Cytomegalovirus (CMV) virus testing.

Eligibility Criteria

Age Range: 18 years to 75 years

Inclusion Criteria: 1. Adult patients over 18 years of age 2. Lung transplant candidates with positive CMV IgG 3. Anticipated to receive a lung transplant (both double lung and single lung) Exclusion Criteria: 1. Negative CMV IgG prior transplant 2. Pregnant or breastfeeding women 3. HIV infected patients 4. Combined organ (e.g., lung-heart, lung-kidney) transplant candidates

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Lung Diseases

Locations

University of Miami

Miami, Florida 33136

United States